• Login
    View Item 
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    •   Home
    • The Manchester Institute Cancer Research UK
    • All Paterson Institute for Cancer Research
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Is tumor cell radiation resistance correlated with metastatic ability?

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Suit, H
    Allam, A
    Allalunis-Turner, J
    Brock, W
    Girinsky, T
    Hill, S
    Hunter, N
    Milas, L
    Pearcey, R
    Peters, L
    West, Catharine M L
    Show allShow less
    Affiliation
    Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston 02114.
    Issue Date
    1994-04-01
    
    Metadata
    Show full item record
    Abstract
    Patients who experience local failure following radiation treatment of epithelial malignancies exhibit a substantially higher rate of distant metastasis than those patients who achieve permanent local control. This fact has raised concern that the local failure to control the primary/regional tumor may serve as a marker of a particularly malignant neoplasm, i.e., high metastatic activity and radiation resistance. If this were true, there would be no gains in survival by increasing the efficacy of treating the primary/regional disease because the new local controls would develop distant metastasis. To investigate this concept, the relationship between distant metastasis probability and tumor cell radiation resistance has been studied by examining laboratory and clinical data (in vitro and in vivo assays) from six collaborating centers. TCD50s (radiation dose which inactivates half of the irradiated tumors) and incidence of distant metastasis in mice with local control have been evaluated for 24 murine tumor systems. SF2s (surviving fraction after 2 Gy) were determined in vitro for cell lines from 8 human, 13 mouse, and 15 rat tumors/tumor sublines and the metastatic activity assessed after injection of the cells into syngeneic murine hosts and xenogenic hosts for the human tumors. SF2s of cells from carcinomas of the head/neck, cervix, and endometrium which were controlled locally by radiation +/- surgery from four centers were compared for those which did and those which did not metastasize. The total number of patients studied was 222. The cumulative distributions of SF2s of locally controlled tumors which did and did not metastasize were not different in each of the data sets. Similarly, there was no demonstrable relationship between TCD50s and metastatic frequency in local control mice. Furthermore, the SF2s of murine and human tumor cell lines did not track with metastatic activity. Radiation sensitivity of clinical and laboratory tumors did not correlate with metastatic activity in studies of data from six centers.
    Citation
    Is tumor cell radiation resistance correlated with metastatic ability? 1994, 54 (7):1736-41 Cancer Res.
    Journal
    Cancer Research
    URI
    http://hdl.handle.net/10541/96080
    PubMed ID
    8137288
    Type
    Article
    Language
    en
    ISSN
    0008-5472
    Collections
    All Paterson Institute for Cancer Research

    entitlement

    Related articles

    • Influence of cellular radiation sensitivity on local tumor control of human melanoma xenografts given fractionated radiation treatment.
    • Authors: Rofstad EK
    • Issue date: 1991 Sep 1
    • Analysis of radiation therapy for the control of Merkel cell carcinoma of the head and neck based on 36 cases and a literature review.
    • Authors: Lawenda BD, Arnold MG, Tokarz VA, Silverstein JR, Busse PM, McIntyre JF, Deschler DG, Baldini EH, Kachnic LA
    • Issue date: 2008 Nov
    • The tumor bed effect: increased metastatic dissemination from hypoxia-induced up-regulation of metastasis-promoting gene products.
    • Authors: Rofstad EK, Mathiesen B, Henriksen K, Kindem K, Galappathi K
    • Issue date: 2005 Mar 15
    • Local tumor control following single dose irradiation of human melanoma xenografts: relationship to cellular radiosensitivity and influence of an immune response by the athymic mouse.
    • Authors: Rofstad EK
    • Issue date: 1989 Jun 15
    • Delayed regional metastases, distant metastases, and second primary malignancies in squamous cell carcinomas of the larynx and hypopharynx.
    • Authors: Spector JG, Sessions DG, Haughey BH, Chao KS, Simpson J, El Mofty S, Perez CA
    • Issue date: 2001 Jun

    Related items

    Showing items related by title, author, creator and subject.

    • Thumbnail

      Treatment for non small cell lung cancer, small cell lung cancer and pleural mesothelioma within the EORTC Lung Cancer Group: past, present and future.

      O'Brien, M; van Meerbeeck, J; Surmont, V; Faivre-Finn, Corinne (2012)
    • Thumbnail

      Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2.

      Ingham, S; Warwick, J; Buchan, I; Sahin, S; O'Hara, Catherine; Moran, Anthony; Howell, Anthony; Evans, D; Centre for Health Informatics, Institute of Population Health, The University of Manchester, Manchester, UK. (2013-06)
      Mutations in BRCA1/2 genes confer ovarian, alongside breast, cancer risk. We examined the risk of developing ovarian cancer in BRCA1/2-positive families and if this risk is extended to BRCA negative families.
    • Thumbnail

      AZD8186 study 1: phase I study to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumour activity of AZD8186 in patients with advanced castration-resistant prostate cancer (CRPC), squamous non-small cell lung cancer, triple negative breast cancer and with PTEN-deficient/mutated or PIK3CB mutated/amplified malignancies, as monotherapy and in combination with vistusertib (AZD2014) or abiraterone acetate.

      Lillian, S; De Bono, J; Higano, C; Shapiro, G; Brugger, W; Mitchell, P; Colebrook, S; Klinowska, T; Barry, S; Dean, Emma J; et al. (2016-12)
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.